Biogen BIIB Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Contract manufacturing, royalty and other revenue | $732.9M+12.3% | $652.6M-27.4% | $899.3M+85.4% | $485.1M+1.8% | |
| Other | $197.2M+139% | $82.5M— | —— | $13M-7.1% | |
| Total Revenue by Product | |||||
| AVONEX | $695.5M-1.7% | $707.5M-12.8% | $811M-16.7% | $973.5M-19.5% | |
| BENEPALI | $453.2M-5.4% | $479.1M+9.2% | $438.8M-0.5% | $441M-11.5% | |
| BYOOVIZ | $32.4M-11.5% | $36.6M+15.5% | $31.7M+637% | $4.3M— | |
| FAMPYRA | $1.4M-98.0% | $71.7M-20.8% | $90.5M-6.3% | $96.6M-8.3% | |
| FLIXABI | $52.6M-16.8% | $63.2M-18.3% | $77.4M-4.8% | $81.3M-18.2% | |
| FUMADERM And ADUHELM | $2.1M-79.6% | $10.3M+1.0% | $10.2M-21.5% | $13M— | |
| IMRALDI | $190.2M-10.7% | $213.1M-4.1% | $222.1M-1.1% | $224.5M-3.8% | |
| PLEGRIDY | $250.1M-4.0% | $260.5M-11.6% | $294.7M-11.2% | $331.9M-7.1% | |
| QALSODY | $86.9M+168% | $32.4M+449% | $5.9M— | $0— | |
| SKYCLARYS | $520.5M+36.1% | $382.5M+584% | $55.9M— | $0— | |
| SPINRAZA | $1.55B-1.7% | $1.57B-9.6% | $1.74B-2.9% | $1.79B-5.9% | |
| TECFIDERA | $679.7M-29.7% | $967.1M-4.5% | $1.01B-29.9% | $1.44B-26.0% | |
| TOFIDENCE | $700K-36.4% | $1.1M— | $0— | $0— | |
| TYSABRI | $1.67B-2.9% | $1.72B-8.6% | $1.88B-7.6% | $2.03B-1.6% | |
| VUMERITY | $746.8M+18.9% | $628M+9.0% | $576.3M+4.1% | $553.4M+34.8% | |
| ZURZUVAE | $195.1M+170% | $72.2M+4,413% | $1.6M— | $0— | |
| After Second GAZYVA Threshold Date by Product | |||||
| GAZYVA | 140%0.0pp | 140%-2.5pp | 142.5%— | —— | |
| RITUXAN | 140%0.0pp | 140%0.0pp | 140%— | —— | |
| Share of non-controling interest recognized by Product | |||||
| Alzheimer's collaboration revenue | 200%0.0pp | 200%— | —— | —— | |
| Percentage of royalties as per collaboration by Product | |||||
| SPINRAZA | 15%0.0pp | 15%0.0pp | 15%0.0pp | 15%0.0pp | |
| VUMERITY | 16%+1.0pp | 15%0.0pp | 15%0.0pp | 15%0.0pp | |
| Estimated additional payments upon achievement of development and commercial milestones by Product | |||||
| Felzartamab And Izastobart/HIB210 | $2.56B— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Biogen break its business down?
- Biogen (BIIB) reports revenue by product across 2 parts — Contract manufacturing, royalty and other revenue and Other. Each is extracted from the segment footnotes and tracked over time.
- Where does Biogen's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Biogen's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
